Tag: tasquinimod

February 9, 2022 Off

Active Biotech in license agreement with Oncode Institute for tasquinimod in myelofibrosis

Active Biotech, a Sweden- based biotechnology company, has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).

April 12, 2017 Off

Active Biotech wins FDA’s Orphan Drug Designation for its multiple myeloma drug

By Dino Mustafić

U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.